Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice

R. Buchbinder, S. Hall, P. N. Sambrook, G. D. Champion, A. Harkness, D. Lewis, G. O. Littlejohn, M. H. Miller, P. F.J. Ryan

Research output: Contribution to journalArticleResearchpeer-review

Abstract

To determine whether methotrexate (MTX) maintains its effectiveness in rheumatoid arthritis (RA) in the setting of community based private rheumatology practice we used life table analysis to review the combined experience of a group of these practices. Of 587 patients with RA who started to take MTX, total termination rate at 70 months was 24.4% with most terminations prompted by drug toxicity. Older age (greater than 65 years) was associated with higher rates of toxicity. Treatment termination rates varied substantially between rheumatologists. We conclude that MTX therapy for RA is well tolerated and maintains effectiveness for at least 70 months.

Original languageEnglish
Pages (from-to)639-644
Number of pages6
JournalJournal of Rheumatology
Volume20
Issue number4
Publication statusPublished - 1 Jan 1993
Externally publishedYes

Keywords

  • life table analysis
  • methotrexate
  • rheumatoid arthritis

Cite this

@article{9c618f30f19b41c598a2a4dfca4bd97c,
title = "Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice",
abstract = "To determine whether methotrexate (MTX) maintains its effectiveness in rheumatoid arthritis (RA) in the setting of community based private rheumatology practice we used life table analysis to review the combined experience of a group of these practices. Of 587 patients with RA who started to take MTX, total termination rate at 70 months was 24.4{\%} with most terminations prompted by drug toxicity. Older age (greater than 65 years) was associated with higher rates of toxicity. Treatment termination rates varied substantially between rheumatologists. We conclude that MTX therapy for RA is well tolerated and maintains effectiveness for at least 70 months.",
keywords = "life table analysis, methotrexate, rheumatoid arthritis",
author = "R. Buchbinder and S. Hall and Sambrook, {P. N.} and Champion, {G. D.} and A. Harkness and D. Lewis and Littlejohn, {G. O.} and Miller, {M. H.} and Ryan, {P. F.J.}",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "20",
pages = "639--644",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

Methotrexate therapy in rheumatoid arthritis : A life table review of 587 patients treated in community practice. / Buchbinder, R.; Hall, S.; Sambrook, P. N.; Champion, G. D.; Harkness, A.; Lewis, D.; Littlejohn, G. O.; Miller, M. H.; Ryan, P. F.J.

In: Journal of Rheumatology, Vol. 20, No. 4, 01.01.1993, p. 639-644.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Methotrexate therapy in rheumatoid arthritis

T2 - A life table review of 587 patients treated in community practice

AU - Buchbinder, R.

AU - Hall, S.

AU - Sambrook, P. N.

AU - Champion, G. D.

AU - Harkness, A.

AU - Lewis, D.

AU - Littlejohn, G. O.

AU - Miller, M. H.

AU - Ryan, P. F.J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - To determine whether methotrexate (MTX) maintains its effectiveness in rheumatoid arthritis (RA) in the setting of community based private rheumatology practice we used life table analysis to review the combined experience of a group of these practices. Of 587 patients with RA who started to take MTX, total termination rate at 70 months was 24.4% with most terminations prompted by drug toxicity. Older age (greater than 65 years) was associated with higher rates of toxicity. Treatment termination rates varied substantially between rheumatologists. We conclude that MTX therapy for RA is well tolerated and maintains effectiveness for at least 70 months.

AB - To determine whether methotrexate (MTX) maintains its effectiveness in rheumatoid arthritis (RA) in the setting of community based private rheumatology practice we used life table analysis to review the combined experience of a group of these practices. Of 587 patients with RA who started to take MTX, total termination rate at 70 months was 24.4% with most terminations prompted by drug toxicity. Older age (greater than 65 years) was associated with higher rates of toxicity. Treatment termination rates varied substantially between rheumatologists. We conclude that MTX therapy for RA is well tolerated and maintains effectiveness for at least 70 months.

KW - life table analysis

KW - methotrexate

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0027174534&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 639

EP - 644

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -